SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-010267
Filing Date
2024-02-06
Accepted
2024-02-06 09:07:24
Documents
21
Period of Report
2024-02-06
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea192943-8k_jasper.htm   iXBRL 8-K 38255
2 UNDERWRITING AGREEMENT, DATED AS OF FEBRUARY 6, 2024, BY AND AMONG JASPER THERAP ea192943ex1-1_jasper.htm EX-1.1 283307
3 OPINION OF PAUL HASTINGS LLP ea192943ex5-1_jasper.htm EX-5.1 6485
4 PRESS RELEASE, DATED FEBRUARY 6, 2024 ea192943ex99-1_jasper.htm EX-99.1 10737
5 GRAPHIC ex5-1_001.jpg GRAPHIC 3339
6 GRAPHIC ex5-1_002.jpg GRAPHIC 4753
7 GRAPHIC ex99-1_001.jpg GRAPHIC 6939
  Complete submission text file 0001213900-24-010267.txt   657624

Data Files

Seq Description Document Type Size
8 XBRL SCHEMA FILE jspr-20240206.xsd EX-101.SCH 3928
9 XBRL DEFINITION FILE jspr-20240206_def.xml EX-101.DEF 26833
10 XBRL LABEL FILE jspr-20240206_lab.xml EX-101.LAB 37093
11 XBRL PRESENTATION FILE jspr-20240206_pre.xml EX-101.PRE 25457
22 EXTRACTED XBRL INSTANCE DOCUMENT ea192943-8k_jasper_htm.xml XML 6031
Mailing Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065
Business Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065 6505491400
Jasper Therapeutics, Inc. (Filer) CIK: 0001788028 (see all company filings)

IRS No.: 842984849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39138 | Film No.: 24598279
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)